



Procter & Gamble Health Announces Fourth Quarter and Fiscal Year Results

Sales for the fiscal up by 10%

Sales for the quarter up by 3%

Mumbai, August 29, 2022: Procter & Gamble Health Limited announced today its financial results for the quarter and fiscal year ended 30th June, 2022. In a year impacted by macroeconomic challenges the company recorded sales of ₹ 1,092 crore for the fiscal year ending 30th June 2022, up by 10% Vs year ago supported by strong established brands in healthcare space trusted by healthcare professionals. Profit After Tax (PAT) for the year ended 30th June 2022 is ₹ 193 crores, up by 9%, despite unprecedented commodity inflations during this fiscal.

The company has recorded a strong performance with sales of ₹289 Crores in the Quarter ending June 30th, up by 3% Vs year ago. Domestic sales were up by 8% however quarter performance was impacted by economic and financial challenges in Sri Lanka.

Mr. Milind Thatte, Managing Director, P&G Health India, said, *“We have registered consistent growth in revenue in recent quarters in a challenging environment which saw the industry facing headwinds across many categories. This has been a result of extensive efforts across all fronts to improve awareness and accessibility of our superior, quality products, and better serve our customers, consumers, partners and communities. We continued our efforts to create awareness through integrated campaigns encouraging consumers to identify symptoms and seek timely treatment. Our team stepped up on scientific education efforts for healthcare practitioners through accredited symposiums, roundtables and congresses with leading medical and pharmacy associations. This year, we also launched the ‘P&G Health Academy’, a virtual platform that brings together health experts from across the globe to converge, share and learn. We strengthened our go-to-market strategy through new initiatives that aim to increase reach and distribution. We continued to invest in strengthening public health through our flagship CSR program ‘SEHAT’ (meaning health) with 9 bespoke initiatives, while making strong progress on gender diversity, equality and inclusion through our i-RISE program.”*

The Board of Directors have recommended a final dividend of ₹ 11.50 per Equity Share, for the Financial Year ending June 30, 2022. Considering interim dividend of ₹ 41 per share, total dividend payout for the fiscal will be ₹ 52.50 per share, subject to the approval of final dividend by shareholders of the company at the ensuing 55th Annual General Meeting.

About Procter & Gamble Health Limited:

Procter & Gamble Health Limited is one of India's largest VMS companies manufacturing and marketing vitamins, minerals, and supplements products for a healthy lifestyle and improved quality of life, including Neurobion, Livogen, SevenSeas, Evion, Polybion and Nasivion. Please visit www.pghealthindia.com for the latest news and information about Procter & Gamble Health Limited and its brands.

About Procter & Gamble:

P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Ambi Pur®, Ariel®, Gillette®, Head & Shoulders®, Olay®, Oral-B®, Pampers®, Pantene®, Tide®, Vicks®, and Whisper®. The P&G operates in approximately 70 countries worldwide.

CONTACTS

Media Contacts - Procter & Gamble Health Limited:

- Ruchita Mehra | mehra.r@pg.com
- Paromita Kundu | kundu.p.1@pg.com

Investor Relations Contact:

- Flavia Machado | machado.f.1@pg.com

Registered Office :

Procter & Gamble Health Limited
 CIN: L99999MH1967PLC013726
 Godrej One, 8th Floor, Pirojshanagar,
 Eastern Express Highway, Vikhroli East,
 Mumbai 400 079 | Tel: (91-22) 6866 9000

Site Address:

Procter & Gamble Health Limited
 CIN: L99999MH1967PLC013726
 Usgaon, Ponda Taluka,
 Goa 403 407 | Tel: (91-832) 2347105
www.pghealthindia.com